SRPT Stock Overview
A commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community Narratives
Narratives bring a range of perspectives from our community.
ELEVIDYS Launch And Calculated Expansions Set To Skyrocket Revenue Growth
Sarepta Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$143.45 |
| 52 Week High | US$173.25 |
| 52 Week Low | US$55.25 |
| Beta | 0.89 |
| 11 Month Change | -2.84% |
| 3 Month Change | 16.19% |
| 1 Year Change | 23.66% |
| 33 Year Change | 83.14% |
| 5 Year Change | 57.92% |
| Change since IPO | 267.82% |
Recent News & Updates
Recent updates
Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity
Jul 24Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%
Jul 05
Sarepta Therapeutics: Navigating Elevidys Upside Potential
Jun 17Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Aren't As Good As They Appear
May 08Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
May 05Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Apr 15Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
Apr 11Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 02Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth
Feb 06Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval
Jan 22Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jan 10There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues
Dec 20Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?
Nov 29Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Aug 08Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Apr 30Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Jan 17Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001
Sep 29Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027
Sep 12Sarepta says FDA lifted clinical hold on Duchenne candidate
Sep 06Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Aug 22Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses
Aug 08Sarepta stock soars 19% on plans for US filing for gene therapy for neuromuscular disorder
Jul 29Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?
May 09Sarepta: The DMD Leader
Apr 26Shareholder Returns
| SRPT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.6% | 4.7% | 3.1% |
| 1Y | 23.7% | 15.1% | 24.9% |
Return vs Industry: SRPT exceeded the US Biotechs industry which returned 15.1% over the past year.
Return vs Market: SRPT underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| SRPT volatility | |
|---|---|
| SRPT Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: SRPT has not had significant price volatility in the past 3 months.
Volatility Over Time: SRPT's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 1,314 | Doug Ingram | www.sarepta.com |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program.
Sarepta Therapeutics, Inc. Fundamentals Summary
| SRPT fundamental statistics | |
|---|---|
| Market cap | US$13.68b |
| Earnings (TTM) | US$47.30m |
| Revenue (TTM) | US$1.50b |
289.2x
P/E Ratio9.1x
P/S RatioIs SRPT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SRPT income statement (TTM) | |
|---|---|
| Revenue | US$1.50b |
| Cost of Revenue | US$946.21m |
| Gross Profit | US$558.78m |
| Other Expenses | US$511.49m |
| Earnings | US$47.30m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.50 |
| Gross Margin | 37.13% |
| Net Profit Margin | 3.14% |
| Debt/Equity Ratio | 113.9% |
How did SRPT perform over the long term?
See historical performance and comparison